

## OMALIZUMAB solution for injection (Xolair®) for chronic rhinosinusitis with nasal polyps

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of OMALIZUMAB solution for injection (Xolair®) for chronic rhinosinusitis with nasal polyps.**

### GREY

Omalizumab is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with INC does not provide adequate disease control.<sup>1</sup>

- > This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of chronic rhinosinusitis with nasal polyps should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Clinical Knowledge Summary: [Chronic sinusitis](#) (June 2018)
- > Pan Mersey APC Formulary Chapter 12: [Ear, nose and oropharynx](#)

### References

1. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics; [Xolair 75 mg solution for injection in pre-filled syringe](#) , 31 July 2020. Accessed online 10 September 2020.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.